Company profile
Telix Pharmaceuticals Ltd
NASDAQ:TLXBiotechnology: Pharmaceutical Preparations
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05450744 | phase1 | active_not_recruiting | 2023-04-01 | 2027-06-01 | Telix Pharmaceuticals (Innovations) Pty Limited | 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) |
| NCT04786847 | phase1 | completed | 2022-01-30 | 2023-09-30 | Telix Pharmaceuticals (Innovations) Pty Limited | 177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study |
| NCT04726033 | — | completed | 2021-08-04 | 2023-12-30 | Telix Pharmaceuticals (Innovations) Pty Limited | 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study) |
| NCT05847348 | phase3 | unknown | 2023-07-19 | 2025-12-30 | Telix Pharmaceuticals (Innovations) Pty Limited | 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
| NCT06750419 | phase3 | recruiting | 2024-11-06 | 2026-06-30 | Telix Pharmaceuticals (Innovations) Pty Limited | 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study |
FDA applications (0)
No records yet.